{"name":"Tris Pharma, Inc.","slug":"tris-pharma-inc","ticker":"","exchange":"","domain":"trispharma.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":8,"colorKey":"oncology","drugs":[{"name":"Amphetamine Extended Release Suspension [Dyanavel]","genericName":"Amphetamine Extended Release Suspension [Dyanavel]","slug":"amphetamine-extended-release-suspension-dyanavel","indication":"Other","status":"marketed"},{"name":"Cebranopadol 100 µg","genericName":"Cebranopadol 100 µg","slug":"cebranopadol-100-g","indication":"Other","status":"phase_2"},{"name":"Cebranopadol 400 micrograms","genericName":"Cebranopadol 400 micrograms","slug":"cebranopadol-400-micrograms","indication":"Other","status":"phase_1"},{"name":"GRT6005","genericName":"GRT6005","slug":"grt6005","indication":"Treatment of chemotherapy-induced nausea and vomiting","status":"phase_2"},{"name":"High Dose GRT6005","genericName":"High Dose GRT6005","slug":"high-dose-grt6005","indication":"Other","status":"phase_2"},{"name":"Low Dose GRT6005","genericName":"Low Dose GRT6005","slug":"low-dose-grt6005","indication":"Other","status":"phase_2"},{"name":"Qualification","genericName":"Qualification","slug":"qualification","indication":"Other","status":"phase_1"},{"name":"Tramadol 600 mg","genericName":"Tramadol 600 mg","slug":"tramadol-600-mg","indication":"Other","status":"phase_1"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Cebranopadol 600 µg","genericName":"Cebranopadol 600 µg","slug":"cebranopadol-600-g","indication":"Chronic pain","status":"phase_2"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"TRI102","genericName":"TRI102","slug":"tri102","indication":"Major depressive disorder","status":"phase_3"}]}],"pipeline":[{"name":"Amphetamine Extended Release Suspension [Dyanavel]","genericName":"Amphetamine Extended Release Suspension [Dyanavel]","slug":"amphetamine-extended-release-suspension-dyanavel","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cebranopadol 100 µg","genericName":"Cebranopadol 100 µg","slug":"cebranopadol-100-g","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cebranopadol 400 micrograms","genericName":"Cebranopadol 400 micrograms","slug":"cebranopadol-400-micrograms","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cebranopadol 600 µg","genericName":"Cebranopadol 600 µg","slug":"cebranopadol-600-g","phase":"phase_2","mechanism":"Cebranopadol is a kappa opioid receptor agonist and mu opioid receptor agonist.","indications":["Chronic pain"],"catalyst":""},{"name":"GRT6005","genericName":"GRT6005","slug":"grt6005","phase":"phase_2","mechanism":"GRT6005 is a small molecule drug that targets the serotonin receptor.","indications":["Treatment of chemotherapy-induced nausea and vomiting"],"catalyst":""},{"name":"High Dose GRT6005","genericName":"High Dose GRT6005","slug":"high-dose-grt6005","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Low Dose GRT6005","genericName":"Low Dose GRT6005","slug":"low-dose-grt6005","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Qualification","genericName":"Qualification","slug":"qualification","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TRI102","genericName":"TRI102","slug":"tri102","phase":"phase_3","mechanism":"TRI102 is a medication that works by inhibiting the reuptake of serotonin and norepinephrine.","indications":["Major depressive disorder"],"catalyst":""},{"name":"Tramadol 600 mg","genericName":"Tramadol 600 mg","slug":"tramadol-600-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxOU3NVOE9Xckt5aE91cXNxZ1NDdE0zUWF3YW9sSWg1b1h5MVYzTWYzZHFSd1YyeG9ZOUhUS1BMQmhBZW1oYl9mMjE1bTFoMF9lZGtSTktzSGRBOC1pdWRkT04yc1UyNHJfNllVbUxYamZZeUFjeEZacTBNbjB0RjNhb0NvLVNTa0p5akE?oc=5","date":"2026-04-08","type":"trial","source":"Yahoo Finance UK","summary":"Tris Pharma to Showcase Encore Phase 3 Data Supporting Continued Progress in Acute Pain Treatment at ASRA 2026 Meeting in Phoenix - Yahoo Finance UK","headline":"Tris Pharma to Showcase Encore Phase 3 Data Supporting Continued Progress in Acute Pain Treatment at ASRA 2026 Meeting i","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNalpNVmctUjg4Y3Zfczk0Z0c1dzVzOTdYaHhJTjREYjJzX0k1UVlydTZvNUdCc1NWVFZCSll5UEdPYVRtcHlsWXRLajREXy1JSWFUbHJVRnBnbjdFWkxTY0dyMmR1cm10RTNEU3ZaSjV6aDNJbTV1UmtweVk4TVpoTmZ1TUVqeTdVYVE?oc=5","date":"2026-03-06","type":"trial","source":"Yahoo Finance","summary":"Tris Pharma Announces Positive Debut Data from Phase 3 ALLEVIATE-1 and 2 Trials Evaluating Cebranopadol in Acute Pain at AAPM PainConnect 2026 Annual Meeting - Yahoo Finance","headline":"Tris Pharma Announces Positive Debut Data from Phase 3 ALLEVIATE-1 and 2 Trials Evaluating Cebranopadol in Acute Pain at","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMixgJBVV95cUxPWDNxZmphMkE0WnltcWxmSWMwX0twTzVwbmRTeXkxNkpIWk5TS2hqS2dPNWtqWkRGVHYzT0RtZkxhYzQzTktTV2t6OFBiQzAzV2F1eThJSlFDVi1Xak5aUWVsYnBWMHV1cjdLWTRPT1gtNExINXJLdnJLVEpZcmlYQjlJZzJfelNTOU5SUmVHazdwN2k2VTFSdm91MFdoeW9GeDhTOFFhUmFGbU56UXhkdWJkTUVldXZ1SkFiamdvaHJLM25Td2hoQmVTLWdnNXp3ZUhTVVU2NkhUdmpUZnlDUmJScEV5c0lqQmdRTGlEbmQ4dVlEc3UtYXRYdXZUYnA4NWpQZ2t5N1hmUndlMl9FQzZNdjhPX2dwWkNMWWFfQ0trUHFYbldPYlFVVlZEMGNfMjk2RXBYXzlPVzFLX00xQkpHdWlSQQ?oc=5","date":"2026-01-08","type":"pipeline","source":"globenewswire.com","summary":"Tris Pharma Announces Acceptance of New Publication - globenewswire.com","headline":"Tris Pharma Announces Acceptance of New Publication","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTFAyczZsY2JBUW5VLVRhNzU5OXFpZUZjTXVHYkRnOFBxRVZvenowQkRDYnUyNFl3ZEg1S3pwdG9TNHg4NHBzenFwZmwxLUFHbmJBZzR6a29QWkU3M2NRUGlhQUJKYXNLQUhGTG1PQjJ4dldua0FhS2o0?oc=5","date":"2025-12-11","type":"pipeline","source":"BioSpace","summary":"9 Companies Hiring in New Jersey - BioSpace","headline":"9 Companies Hiring in New Jersey","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxNUGhyR1R4aDJ4bExFUjU3ZWxMU2xPZUNTTk9FNjJ2dEVoVldJY1lXZWliSEdlNDRJUEFJUG5ZUlNobXVER2VRdXlTY2puMno0REV3aHFBMlhXNVZ3a0JWd2ZuMDNEb3BuSzMwN3B2UkFDX2FsYUY1TjJTUmRvSzJUdFR3SXNIQXItWERVZU41bjdXTFVhZm1mVkZ6UnBXOGF6TzJOaU1NRWRrdjF3Z0ppN3FxVFlZck1iYmRqNTFHYmprNU0xT1o3TUJKOFJ0OXpJN3V5M3QzLXZWaWFCUjkzMV9kb2YyYkc3UlhHbjktVzJIcDZSVGFrOFZyaFpnS2V2bi1nbU9xOFpwMk1fY3RtaW1iM3Y?oc=5","date":"2025-12-09","type":"regulatory","source":"Business Wire","summary":"Tris Pharma Announces FDA Acceptance of NDA for Once-Nightly, Low-Sodium Oxybate Product for Narcolepsy and Idiopathic Hypersomnia - Business Wire","headline":"Tris Pharma Announces FDA Acceptance of NDA for Once-Nightly, Low-Sodium Oxybate Product for Narcolepsy and Idiopathic H","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwJBVV95cUxOZ2pmVXlSTDh5dGlRampLRkJYaE5NSGlCMHRqNXQyaFVBUHk2X2dUNlFYd0tzTVo2aG5LWWIxdkNfZDRLRjhhcXdMT0RXMnlPdHNBeE9vNVVwUTB2M2RJdlBmR3VWTVZqVWpRMGFDN2tRclBsaDU0YlFHZmlDRDB6eUw0cHJhOUR2WDdZSXRjY3g3TnFlbXQ2SFVQcUdFU0ZYRmQwYnN2anJpV2c5c2lLOGt2RXE5TTRDVEFxT2UyQ3kzMjRENE5sZXVDaXVmaGpQdldLbGtvZ21HeUk0TmdCMTZiMDBUcnRpQTZXV0JVNi1iQjFGNUVYMDZuUno3RDlnUkVFZGJmLVJrc2hiMDg2UkRGOA?oc=5","date":"2025-12-09","type":"regulatory","source":"Regulatory Oversight","summary":"Texas AG Secures $41.5M Settlement With Pfizer and Tris Pharma Over Allegedly Adulterated ADHD Drug: What Health Care Stakeholders Should Know - Regulatory Oversight","headline":"Texas AG Secures $41.5M Settlement With Pfizer and Tris Pharma Over Allegedly Adulterated ADHD Drug: What Health Care St","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPN0locURoVnJTZEhvLTl1UmY2NWtTTHM0b3JoWnAyU0RvUG4zNTh2eEExUU1vRENiSjI2T1Z5MkRGLXdTNXNQLVpLM1JvODIwLU8zQUVTRTRoSlQwbE81TkpPT1dXcUtsYk1OZEt1N3FtYlU4MHV5MWdJclNTVXAwbGZaNU5XTVRGVmNGaU93V0QzVDhrSjlZMnVoa1VwdFBpLVdqR0oyRkhJNE9HYWd5d1NXSk83Zw?oc=5","date":"2025-11-20","type":"deal","source":"Fierce Pharma","summary":"Pfizer, Tris Pharma ink $41.5M deal to settle ADHD drug fraud allegations in Texas - Fierce Pharma","headline":"Pfizer, Tris Pharma ink $41.5M deal to settle ADHD drug fraud allegations in Texas","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPOVFmOGpqNWNIcTlQd1FScV9kcG03Z2N4VWZqbTZiNjJaR0NiNklhdjVuUTctc0p6S1FpUDM4QzJjcl9YRDBZbDR1SklpQTBDVFlHZDBwZFdUc3ZFMmlIRmk2bzhacG5keWRWQTNyRGRPNkUzbXJTQUJZU0pEU0h1eUlaWjVSUURfZkhyTDdMQmh6VkF5TGRKWm5IUUdHTlRHdjRJWTR3?oc=5","date":"2025-11-19","type":"pipeline","source":"Bloomberg Law News","summary":"Pfizer, Tris Pharma To Pay Texas $41.5 Million in ADHD Drug Suit - Bloomberg Law News","headline":"Pfizer, Tris Pharma To Pay Texas $41.5 Million in ADHD Drug Suit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOTXBBNjRiWmRQemI2amNrWmlWWTFucXhoZEktcUlSMWo4Q3J0Q1pHOVNPbnBBaUllazcyNUNnMm8yRXo4ZDBLbXBUaS1sNGxCN3I0VnZGVWxFZFNtbkZBbjJIaFM3MGhHWUc5cFBuTEpuU3I5aFVnRTk4blN3MEFzUmh5THZ5OGNhVmRPclUwMG9GR1pmTGpFcDdKdWpHUndIaGo4emxGakdGMGt5cHZzVms5N2J1emtXdHY00gFyQVVfeXFMTXdzWU1FUnVQa3ZPWWVuTml4VXpGblo4UjBJRHJKSjNVb25lS09Sb1JRV0ZxOXgxcy0ycFJBN0M5YU1xT1pONHhtM1plalhvMlR6aEZMdDNseXd4bjdzWURWMWtSU1NrUGwwMXJmTUZUZXpB?oc=5","date":"2025-11-19","type":"pipeline","source":"Law360","summary":"Pfizer To Pay $41.5M To Settle Adulterated ADHD Drug Claims - Law360","headline":"Pfizer To Pay $41.5M To Settle Adulterated ADHD Drug Claims - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxNUXVnMUxfMlB2anlnX05sOWNEb09KZGlYQlZjR3JHazEyY2NjcTQzOTRqVEQzZXlrZFJBaEYzVEY0all6dU9fa1pRSGtZMzN6SkQ1YTVKejVNQjJLTzA1NkZHd0pnQWFncW5JMTNlRGNLcTVKTGxLdHNHZkJPbmpHU1ZfUFFvSjVRaGlLSEg1TjZJY1FPbXhaVUREbDlOTWRRMHJHbWMzNlQ4UTJMdHFfRHhqNU01SlRrLWRlT1JDc21yQy1UNFBRZk5vX3pXMDZCcXFtdlEyNjBEWmhPdEw5NEl2YVlUZjBaZTlVOUxDUXg0VEhzQUJPUG5OT2xfSkdMa0puS21BNEVaNDVIVnNqQ3diN01BVDhCV3VINlRjcGxqTFExWmppM3k3UHZDS3dwR3c?oc=5","date":"2025-10-16","type":"pipeline","source":"Business Wire","summary":"Tris Pharma Announces Acceptance of New Review Article Highlighting Challenges of Treating Moderate-to-Severe Acute Pain with Currently Available Drugs - Business Wire","headline":"Tris Pharma Announces Acceptance of New Review Article Highlighting Challenges of Treating Moderate-to-Severe Acute Pain","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxOVEFpWUh6OVhLdkxDY3lYLWRQU3hWdnd1N1pqOVZEempRdDRadVdZaGZXN1lfekhWempoN0pMekl6d2N0cDVqWFI3SzdtNFoxOGdSaFdTdzdxNTZDOG14LU40Q240UVVNSlpsdHBqMFZFcGhodUY5NVBmWTBDdE1hT1VtZldoRExndTBuUFVMd1RyUTBrYWZGZFByMDBWT0ZzUHNBZUI3dzlCdmJJcEdkODMtY0VPb3VSb0VyeUdER0pfQy0yanptQ3NUck5hcDNDUFNIWnl5ZW1TOGh1Z0l4YnFn?oc=5","date":"2025-08-06","type":"deal","source":"PR Newswire","summary":"Pulse Health partners with Tris Pharma to Power Omnichannel HCP Engagement for ADHD Products - PR Newswire","headline":"Pulse Health partners with Tris Pharma to Power Omnichannel HCP Engagement for ADHD Products","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQN0QtSjBZQlFmZkE5R2tha2l3eUlKWWpNYXp3SXVKVUo1Q1hHeXkwcWNESGd0SWc2dUd2SHpUdUh1cVliU2c4MjZrZmlWSGNnWVpvSElXODVtdW82bzZfMkNqeHNWMThlU1lycG1BNHhPNXNZSS1JOFdNWjhsQkx0Z0FZWXVoNHI3X0tSODZHeEVpUWFRWkx1Vmx2RFZwVGM4X3VDVEN6U2s?oc=5","date":"2025-06-03","type":"pipeline","source":"Bloomberg Law News","summary":"NJ Drugmaker Beats Texas Suit Alleging ADHD Medicine Adulterated - Bloomberg Law News","headline":"NJ Drugmaker Beats Texas Suit Alleging ADHD Medicine Adulterated","sentiment":"neutral"}],"patents":[],"drugCount":10,"phaseCounts":{"marketed":1,"phase_2":5,"phase_1":3,"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}